En préparation
POA (Pragmatic Use of Long-Acting Oral ART in Africa)
To demonstrate the non-inferiority of LENACAPAVIR 300 mg/ISLATRAVIR 2 mg (once weekly) compared with the approved standard first-line treatment (tenofovir/lamivudine/dolutegravir) (once daily) in people living with HIV (adolescents ≥ 18 years of age and adults)
Project Details
Principal Investigator
Stéphane N’Goran
Duration
71 months
Sponsor
EDCTP
Study start
01 Feb 2026
Objectives
Main Objectives
To demonstrate the non-inferiority of LENACAPAVIR 300 mg/ISLATRAVIR 2 mg (once weekly) compared with the approved standard first-line treatment (tenofovir/lamivudine/dolutegravir) (once daily) in people living with HIV (adolescents ≥ 18 years of age and adults)
Research Team
The research team has not yet been filled in for this project.
Collaborate with us
We are open to partnerships with international research institutions and doctoral students.
Research Request
Estimated response time: 3-5 business days.
Keywords
OUR PROJECTS
COHORTE
